LifeArc Ventures invests in Maxion Therapeutics

Investment in Maxion Therapeutics to drive antibody development for previously untreatable ion channel and GPCR-driven diseases

LifeArc Ventures invests in Surgery Hero, world’s first digital coaching clinic for patients

Seed funding will be used to scale the solution through the application of machine learning

AbbVie acquires LifeArc portfolio company DJS Antibodies

AbbVie will pay DJS shareholders approximately $255 million in cash at closing for the acquisition of DJS

LifeArc portfolio company Ducentis BioTherapeutics acquired by Arcutis Biotherapeutics for up to $400 million

First exit for LifeArc Ventures, the largest investor in Ducentis, recognising the transformational potential of its science

LifeArc co-founded company RQ Bio signs licensing agreement with AstraZeneca worth up to $157m plus royalties for monoclonal antibodies against SARS-CoV-2

AstraZeneca granted exclusive worldwide licence to develop, manufacture and commercialise RQ Bio’s existing early-stage monoclonal antibodies (mAbs)…

LifeArc participates in Series A funding round for company developing pioneering new gene therapies for neurodegenerative diseases

Helping to progress an innovative gene therapy platform from the bench to a stage where it is progressing closer to the clinic.

LifeArc unveils new strategy and £1.3 billion spend to drive life-changing science

Aims to transform the way diseases such as motor neurone disease are prevented, identified and treated.

10 new data-driven health companies selected for KQ Labs accelerator programme

10 innovative start-up companies working at the interface of biomedical and data science are to receive personalised…

LifeArc invests in company developing personalised drug and digital combination treatments

LifeArc and partners announce a £13 million financing deal in Closed Loop Medicine to enable the company to develop further and faster.